CABA Texas Chapter Team
President
Shautong (Xiaotong) Song is the founding CEO of Icell Kealex
Therapeutics, an oncology startup biotech company based at the
JLABS@TMC in Houston, TX. Icell Kealex Therapeutics is developing a
novel oncolytic virus armed with T-cell engaging antibody fragments
that boost the virus’ antitumor efficacy. The company is entering
Phase I trials for solid tumors with its lead product in 2017-2018.
Shautong is also the founding CSO of Anhui Weiming Cell Therapy Inc
in Anhui, PR China. Prior to founding these companies, Shautong was
a tenure track faculty at Baylor College of Medicine from 2010 to 2016.
Shautong has been focus on the development of novel cancer
immunotherapies including oncolytic virus, CAR-T, and bi-specific antibodies. His research work
at BCM had been funded by NIH R01 and DOD grants. He has more than 30 publications in
peer-reviewed journals and book chapters, as well as more than 10 patents. Shautong received
his BS degree in Preventive Medicine from Peking University Health Center (Previous Beijing
Medical University), Ph.D. in Molecular Immunology from Nanjing Medical School.
Executive Committee Members
Tom Tong is an International Partner with the international law firm of
Locke Lord LLP. Having been practicing law in Texas and Massachusetts
for over 17 years, Tom has advised hundreds of U.S. and China based
clients in their business formation, corporate financing, mergers and
acquisitions, and commercial lawsuits. Tom maintains close professional
relationship with a number of well-known physicians and research
scholars in some of the nation’s leading medical institutions, and has
advised numerous entrepreneurs in their business ranging from
traditional pharmaceutical start-ups to modern telemedicine. Tom also
represented some U.S. medical device companies in their manufacturing and licensing
transactions with various Chinese companies.
Tom is one of the first bilingual M&A attorneys in the U.S. to assist Chinese companies in acquiring U.S. business assets through bankruptcy proceedings, the first to introduce Chinese oil drilling companies to operate in the U.S. a decade ago, and among the most experienced U.S. based attorneys for cross-border transactions between U.S. and China. In recent years Tom has represented a Chinese state-owned company in a $1.9 billion acquisition bid for a U.S. general aviation manufacturing company; a Chinese public company in a $1.1 billion bid for the acquisition of an industrial automation industry company, and a few U.S.-China joint ventures in their financing transactions. Tom has also represented Sinopec, CNPC, Sinochem and many other China based companies in a number of successful litigation matters in the U.S. some of which involved claims exceeding $1.3 billion. Tom and his firm of more than 800 lawyers have been recognized by various civic groups for their long-standing support for the Chinese communities in Texas.
Tom holds his Bachelor’s degree from Shandong University, MBA from Rollins College, and JD from Vanderbilt University School of Law.
Jim (Baojian) Wu is cureently the President of US-China International
Business Network & PetroStone Energy LLC, Co-Founder of Club 1898 LLC,
and Chairman of Houston International Trade Development Council
Mr. Wu has over 20 years of experience in importing and exporting,
sourcing and outsourcing, identifying new markets for established
products, setting up distribution networks, and training and coaching of
international business cultures. Mr. Wu was born and raised in China. He
began his International business career after he earned a B.M. from
Medical School of Beijing University in China and an MBA from Bauer
Business School at University of Houston. Mr. Wu is an innovative, dedicated, and energetic
international expert whose background is ideally suited for business and trade development
between the United States and China.
Ze Tian is an Institute Research Scientist at ORBIT, MD Anderson and lead the
in vivo effort for antibody drug discovery in the field of oncology. Prior to
ORBIT, She was a staff scientist and head of in vivo at Curis.Inc. Before joined
industry, she was an Instructor and faculty member in the department of
Medical Oncology at Dana Farber Cancer Institute and Harvard Medical School
with research focusing on anti-cancer drug discovery from small molecules in a
variety of signaling pathways. She has published more than 50 papers in peer-
reviewed journals, including Cancer Cell and Blood. She received a Ph.D. in Pharmacology from
Peking Union Medical College and a B.S. from Peking University.
Weimin Xiao is working on Efung Venture Capital Limited Company in
Shenzhen as Vice President and Partner to Lead the Private Equity &
Venture Capital Investment in the fields of Pharmaceuticals, Biotechnology
and Medical Devices. Prior to working at Efung, he was a research scientist
in University of Houston, where he was working on Next Generation
Sequencing. Before came to Houston in 2004, he had been working in the
Department of Pathophysiology, Xiangya Medical School for 10 years. He
holds Bachelor degree in Clinical Medicine, Master and Ph.D. degree in
Pathology and Pathophysiology. He has over 20 years’ experience in Biomedicine research and
has authored over 20 peer reviewed papers, 4 years’ experience in VC/PE investment focusing
on health care.
Mr. Jun Lu currently serves as the vice president and managing partner of
Vesalius Ventures, a Houston based venture capital accelerator focusing
on early stage companies in telemedicine, mHealth, and other medical
technology in the US and China. His investment and incubating projects
include a leading cardiac monitoring service provider in China, Tianjin
Guangyi Medtech, JSA Health Telepsychiatry, LifeBot, SALUS, etc. He also
served several US medical technology companies as an advisor, to help
them expand business in China. Mr. Lu is also working with the American
Telemedicine Association and the Tianjin Municipal Government and the Tianjin Binhai High-
tech Industrial Development Zone, to develop the first China International Exhibition of
telemedicine technology.
Mr. Lu also leads the development of VesaliuX, a cross-border healthcare business accelerator
focusing on developing market entry and investment opportunities in China for U.S. healthcare
technology companies. The company is also in the process of raising a seed-fund to invest in
early stage companies.
Prior to Vesalius, Mr. Lu Jun worked as a senior business analyst at a Healthcare IT company in
Houston. He also served as an intern security analyst at BOCI-Prudential Asset Management
Company, a Hong Kong base firm and as a sales engineer at Focus Technology in China.
Mr. Lu received his Master of Business Administration (MBA) degree from Rice University and also earned a Master of Science in Biomedical Science (MS) from the University Texas M.D. Anderson Cancer Center. He completed his undergraduate study at Nanjing University in China.
Mingxuan Xu is currently working as an operations manager in Hitgen
Pharmaceuticals Inc. at Houston TX. Previously she has been working
on translational/clinical research focusing on Epilepsy field at Baylor
College of Medicine as a research staff. Before joined BCM, she was a
postdoctoral researcher at Ohio State University, studying the
underlying mechanisms for ion channel protein targeting. She has GLP
and GCP experiences. She received her Ph. D in Microbiology from
Shanghai institute for biological sciences, Chinese Academy of
Sciences. During her Ph. D. program, she studied the genetic functions
of Streptomyces, which is one of the most important industrial bacteria as a major resource for
antibiotics production. She received her master and bachelor degree from Shengyang
Pharmaceutical University. She is a well-trained, highly motivated scientist specializing in
Molecular Biology, Biochemistry, Cell biology, Pharmacology and Immunology. She has
published 20 more scientific papers, editorial and conference papers as first author, co-author
and corresponding author.
Shautong (Xiaotong) Song is the founding CEO of Icell Kealex
Therapeutics, an oncology startup biotech company based at the
JLABS@TMC in Houston, TX. Icell Kealex Therapeutics is developing a
novel oncolytic virus armed with T-cell engaging antibody fragments
that boost the virus’ antitumor efficacy. The company is entering
Phase I trials for solid tumors with its lead product in 2017-2018.
Shautong is also the founding CSO of Anhui Weiming Cell Therapy Inc
in Anhui, PR China. Prior to founding these companies, Shautong was
a tenure track faculty at Baylor College of Medicine from 2010 to 2016.
Shautong has been focus on the development of novel cancer
immunotherapies including oncolytic virus, CAR-T, and bi-specific antibodies. His research work
at BCM had been funded by NIH R01 and DOD grants. He has more than 30 publications in
peer-reviewed journals and book chapters, as well as more than 10 patents. Shautong received
his BS degree in Preventive Medicine from Peking University Health Center (Previous Beijing
Medical University), Ph.D. in Molecular Immunology from Nanjing Medical School.Executive Committee Members
Tom Tong is an International Partner with the international law firm of
Locke Lord LLP. Having been practicing law in Texas and Massachusetts
for over 17 years, Tom has advised hundreds of U.S. and China based
clients in their business formation, corporate financing, mergers and
acquisitions, and commercial lawsuits. Tom maintains close professional
relationship with a number of well-known physicians and research
scholars in some of the nation’s leading medical institutions, and has
advised numerous entrepreneurs in their business ranging from
traditional pharmaceutical start-ups to modern telemedicine. Tom also
represented some U.S. medical device companies in their manufacturing and licensing
transactions with various Chinese companies.Tom is one of the first bilingual M&A attorneys in the U.S. to assist Chinese companies in acquiring U.S. business assets through bankruptcy proceedings, the first to introduce Chinese oil drilling companies to operate in the U.S. a decade ago, and among the most experienced U.S. based attorneys for cross-border transactions between U.S. and China. In recent years Tom has represented a Chinese state-owned company in a $1.9 billion acquisition bid for a U.S. general aviation manufacturing company; a Chinese public company in a $1.1 billion bid for the acquisition of an industrial automation industry company, and a few U.S.-China joint ventures in their financing transactions. Tom has also represented Sinopec, CNPC, Sinochem and many other China based companies in a number of successful litigation matters in the U.S. some of which involved claims exceeding $1.3 billion. Tom and his firm of more than 800 lawyers have been recognized by various civic groups for their long-standing support for the Chinese communities in Texas.
Tom holds his Bachelor’s degree from Shandong University, MBA from Rollins College, and JD from Vanderbilt University School of Law.
Jim (Baojian) Wu is cureently the President of US-China International
Business Network & PetroStone Energy LLC, Co-Founder of Club 1898 LLC,
and Chairman of Houston International Trade Development Council
Mr. Wu has over 20 years of experience in importing and exporting,
sourcing and outsourcing, identifying new markets for established
products, setting up distribution networks, and training and coaching of
international business cultures. Mr. Wu was born and raised in China. He
began his International business career after he earned a B.M. from
Medical School of Beijing University in China and an MBA from Bauer
Business School at University of Houston. Mr. Wu is an innovative, dedicated, and energetic
international expert whose background is ideally suited for business and trade development
between the United States and China.Ze Tian is an Institute Research Scientist at ORBIT, MD Anderson and lead the
in vivo effort for antibody drug discovery in the field of oncology. Prior to
ORBIT, She was a staff scientist and head of in vivo at Curis.Inc. Before joined
industry, she was an Instructor and faculty member in the department of
Medical Oncology at Dana Farber Cancer Institute and Harvard Medical School
with research focusing on anti-cancer drug discovery from small molecules in a
variety of signaling pathways. She has published more than 50 papers in peer-
reviewed journals, including Cancer Cell and Blood. She received a Ph.D. in Pharmacology from
Peking Union Medical College and a B.S. from Peking University.Weimin Xiao is working on Efung Venture Capital Limited Company in
Shenzhen as Vice President and Partner to Lead the Private Equity &
Venture Capital Investment in the fields of Pharmaceuticals, Biotechnology
and Medical Devices. Prior to working at Efung, he was a research scientist
in University of Houston, where he was working on Next Generation
Sequencing. Before came to Houston in 2004, he had been working in the
Department of Pathophysiology, Xiangya Medical School for 10 years. He
holds Bachelor degree in Clinical Medicine, Master and Ph.D. degree in
Pathology and Pathophysiology. He has over 20 years’ experience in Biomedicine research and
has authored over 20 peer reviewed papers, 4 years’ experience in VC/PE investment focusing
on health care.Mr. Jun Lu currently serves as the vice president and managing partner of
Vesalius Ventures, a Houston based venture capital accelerator focusing
on early stage companies in telemedicine, mHealth, and other medical
technology in the US and China. His investment and incubating projects
include a leading cardiac monitoring service provider in China, Tianjin
Guangyi Medtech, JSA Health Telepsychiatry, LifeBot, SALUS, etc. He also
served several US medical technology companies as an advisor, to help
them expand business in China. Mr. Lu is also working with the American
Telemedicine Association and the Tianjin Municipal Government and the Tianjin Binhai High-
tech Industrial Development Zone, to develop the first China International Exhibition of
telemedicine technology.
Mr. Lu also leads the development of VesaliuX, a cross-border healthcare business accelerator
focusing on developing market entry and investment opportunities in China for U.S. healthcare
technology companies. The company is also in the process of raising a seed-fund to invest in
early stage companies.
Prior to Vesalius, Mr. Lu Jun worked as a senior business analyst at a Healthcare IT company in
Houston. He also served as an intern security analyst at BOCI-Prudential Asset Management
Company, a Hong Kong base firm and as a sales engineer at Focus Technology in China.Mr. Lu received his Master of Business Administration (MBA) degree from Rice University and also earned a Master of Science in Biomedical Science (MS) from the University Texas M.D. Anderson Cancer Center. He completed his undergraduate study at Nanjing University in China.
Mingxuan Xu is currently working as an operations manager in Hitgen
Pharmaceuticals Inc. at Houston TX. Previously she has been working
on translational/clinical research focusing on Epilepsy field at Baylor
College of Medicine as a research staff. Before joined BCM, she was a
postdoctoral researcher at Ohio State University, studying the
underlying mechanisms for ion channel protein targeting. She has GLP
and GCP experiences. She received her Ph. D in Microbiology from
Shanghai institute for biological sciences, Chinese Academy of
Sciences. During her Ph. D. program, she studied the genetic functions
of Streptomyces, which is one of the most important industrial bacteria as a major resource for
antibiotics production. She received her master and bachelor degree from Shengyang
Pharmaceutical University. She is a well-trained, highly motivated scientist specializing in
Molecular Biology, Biochemistry, Cell biology, Pharmacology and Immunology. She has
published 20 more scientific papers, editorial and conference papers as first author, co-author
and corresponding author.